Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
A. Mean difference in the lumbar spine areal BMD Z-score in published, controlled trials of bisphosphonate therapy for the treatment of children with osteoporosis, with comparison of results for the treatment versus placebo/untreated control groups. Studies were included with the following criteria: 1. At least 10 patients per group; 2. prospective design with a placebo or untreated control arms; 3. available data on either the pre- and post-treatment change in LS BMD Z-score with standard error OR the percent change in LS BMD Z-score. *Details about the magnitude of the mean change in LS BMD Z-score were not reported; however, the effect size with 95% CI was provided. &Seikaly (2005)533 was a placebo-controlled crossover study design with the results from the first year of the study presented. $Bishop (2013)448 reported least-squares mean difference. B. Relative risk of vertebral and non-vertebral Source: Disorders of Calcium, Phosphate, and Bone Metabolism, Pediatric Endocrinology and Inborn Errors of Metabolism, 2e fractures in published, controlled trials of intravenous or oral bisphosphonate therapy for the treatment of children with osteoporosis, with comparison of Citation: K, Hoffmann GF, Roth KS. Pediatric Endocrinology andStudies Inborn were Errorsincluded of Metabolism, 2e; 2017 the number of childrenSarafoglou with fractures in the treatment versus placebo/untreated groups. in the figure if theyAvailable met the at: following criteria: http://mhmedical.com/ Accessed: August 02, 2017 1. At least 10 patients per group; 2. prospective design with a placebo or untreated control arm; and 3. available data on the number of patients with Copyright © 2017 McGraw-Hill Allpublished, rights reserved fractures in each group. C. The incidence Education. rate ratio in controlled trials of intravenous or oral bisphosphonate therapy for the treatment of children with osteoporosis with comparison of the number of fracture events in the treatment versus placebo/untreated control groups. Studies were